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BACKGROUND: Neoadjuvant chemoradiation before surgery is an emerging treatment modality for pancreatic ductal
adenocarcinoma (PDAC). However, analysis of prognostic factors is limited for patients with PDAC treated with neo-
adjuvant chemoradiation and pancreaticoduodenectomy (PD). METHODS: The study population was comprised of
240 consecutive patients with PDAC who received neoadjuvant chemoradiation and PD and was compared with 60
patients who had no neoadjuvant therapy between 1999 and 2007. Clinicopathologic features were correlated with
disease-free survival (DFS) and overall survival (OS). RESULTS: Among the 240 treated patients, the 1-year and 3-
year DFS rates were 52% and 32%, with a median DFS of 15.1 months. The 1-year and 3-year OS rates were 95% and
47%, with a median OS of 33.5 months. By univariate analysis, DFS was associated with age, post-therapy tumor
stage (ypT), lymph node status (ypN), number of positive lymph nodes, and American Joint Committee on Cancer
(AJCC) stage, whereas OS was associated with intraoperative blood loss, margin status, ypT, ypN, number of positive
lymph nodes, and AJCC stage. By multivariate analysis, DFS was independently associated with age, number of posi-
tive lymph nodes, and AJCC stage, and OS was independently associated with differentiation, margin status, number
of positive lymph nodes, and AJCC stage. In addition, the treated patients had better OS and lower frequency of
lymph node metastasis than those who had no neoadjuvant therapy. CONCLUSIONS: In patients with PDAC who
received neoadjuvant chemoradiation and subsequent PD, post-therapy pathologic AJCC stage and number of posi-
tive lymph nodes are independent prognostic factors. Cancer 2012;118:268-77. VC 2011 American Cancer Society.
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Pancreatic cancer is the fourth leading cause of cancer-related death in the United States.1 In 2009, it is estimated
that 42,470 men and women were diagnosed with pancreatic cancer and 35,240 died of disease.1 Up to 80% of patients
with pancreatic ductal adenocarcinoma (PDAC) present with metastatic disease, with a dismal 5-year survival rate of
5.5%.1 Even in patients with localized disease, the 5-year survival rate is only 22%.1 Surgical resection of localized PDAC
is the only potentially curative approach for this deadly disease. However, despite significant improvements in operative
techniques and postoperative mortality rates, the overall survival (OS) for patients with PDAC has not changed signifi-
cantly over the past 4 decades.2 The addition of postoperative adjuvant chemotherapy and/or radiation has been estab-
lished as the standard of care in light of results of prospective randomized controlled trials showing survival benefit with
adjuvant therapy in resected pancreatic cancer patients.3 Recently, several tertiary referral centers worldwide, including
our institution, have demonstrated the safety and feasibility of preoperative neoadjuvant chemoradiation for PDAC.4-8 In
some studies, survival of patients with resectable or borderline resectable PDAC treated with neoadjuvant therapy has
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been shown to exceed historical control.4,8-12 In our insti-
tution, neoadjuvant chemoradiation plays an integral role
in the treatment of patients with PDAC.
Better survival in patients with PDAC who undergo
pancreaticoduodenectomy (PD) has been associated with
pathologic primary tumor (pT) stage I disease,13-15 well-
differentiated histology,13,16-18 negative lymph node sta-
tus,13,15,17-21 and negative resection margins.18,22,23
However, most of these studies have been based on clini-
copathologic data from patients who underwent surgery
alone13,14,17,19,20 or those treated with postoperative che-
moradiation.15,16,18,22-25 It remains unclear whether post-
therapy pathologic stage predicts disease-free and OS in
patients with PDAC treated with neoadjuvant chemora-
diation followed by PD. We, therefore, examined the
prognostic significance of clinicopathologic characteristics
in a large cohort of patients with PDAC who received pre-
operative chemotherapy and/or radiation and subse-
quently underwent PD. Our study showed that post-
therapy pathologic stage, including lymph node status
and the number of positive regional lymph nodes, is an in-
dependent prognostic factor in this group of patients.
MATERIALS AND METHODS
Study Population, Patient Characteristics, and
Follow-up
The study was approved by the institutional review board
of The University of Texas MD Anderson Cancer Center.
Two hundred forty consecutive patients with histologically
confirmed PDAC who received neoadjuvant chemotherapy
and/or radiation therapy and underwent PD (treated
group) at The University of Texas MD Anderson Cancer
Center between January 1999 and December 2007 were
included in this study. This treated group was compared
with 60 consecutive patients who underwent PD alone
with no neoadjuvant therapy (untreated group) during the
same time period. For the purpose of this analysis, patients
who underwent distal pancreatectomy for PDAC and those
who died from postoperative complications were excluded.
Our treated group consisted of 97 women and 143
men, with a mean age of 62.5 years at the time of surgery
(median, 62.9 years; range, 38.5-85.4 years). Neoadju-
vant regimens are listed in Table 1. One hundred nineteen
patients (50%) received neoadjuvant chemoradiation,
114 patients (47%) received neoadjuvant systemic chem-
otherapy followed by chemoradiation, and the remaining
7 patients (3%) received neoadjuvant systemic chemo-
therapy alone. One hundred forty-six of 240 patients
(61%) were treated on protocols; 77 (32%) received gem-
citabine-based chemoradiation,4 and 69 patients (29%)
received systemic chemotherapy with gemcitabine and cis-
platin followed by gemcitabine-based chemoradiation.8
All patients underwent restaging evaluation after comple-
tion of neoadjuvant therapy, and PD was performed only
in patients with resectable disease who did not develop
disease progression or metastasis and had no contraindica-
tions for major abdominal surgery. The average intraoper-
ative blood loss was 900 mL (range, 100-6000 mL). The
patients’ clinical follow-up information through Decem-
ber 2009 was extracted from patient medical records and
review of the US Social Security Index when necessary.
Recurrence status was updated at each follow-up clinic
visit.
Pathologic Evaluation
A standardized system for the pathologic evaluation of
PD specimens has been used at our institution since July
1990. All cases were re-reviewed by a gastrointestinal pa-
thologist (Huamin Wang) for tumor type, size, differen-
tiation, extrapancreatic tissue involvement, margin status,
and number of positive regional lymph nodes. The patho-
logic primary tumor classification and stage grouping
were determined according to the American Joint Com-
mittee on Cancer (AJCC) Staging Manual, seventh edi-
tion.26 The final margin status of PD specimens was
recorded as R0 (negative surgical margins microscopi-
cally), R1 (negative surgical margins grossly but with mi-
croscopic presence of tumor cells, including carcinoma in
Table 1. Neoadjuvant Chemotherapy and Radiation Therapy Received by the Patients
Neoadjuvant Therapy No. of Patients
Group 1: Fluoropyrimidine-based chemoradiationa 42
Group 2: Gemcitabine-based chemoradiation 77
Group 3: Systemic chemotherapy followed by gemcitabine-based chemoradiation 77
Group 4: Systemic chemotherapy followed by fluoropyrimidine-based chemoradiationa 37
Group 5: Chemotherapy alone 7
a Fluoropyrimidine comprises either 5-fluorouracil or capecitabine (XELODA).
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situ/high-grade dysplasia, at any resection margin), or R2
(presence of grossly identifiable tumor at any margin).
Statistical Analysis
Chi-square analysis or Fisher exact tests were used to com-
pare categorical data, and analysis of variance was used to
compare continuous variables. Survival curves were con-
structed using the Kaplan-Meier method, and the log-
rank test was used to evaluate the statistical significance of
differences. Disease-free survival (DFS) was calculated as
the time from the date of surgery to the date of first recur-
rence after surgery (in patients with recurrence) or to the
date of last follow-up (in patients without recurrence). OS
was calculated as the time from the date of diagnosis to
the date of death or the date of last follow-up (if death did
not occur). The prognostic significance of clinical and
pathologic characteristics was determined using univariate
Cox regression analysis. Cox proportional hazards models
were fitted for multivariate analysis. After interactions
between the variables were examined, a backward stepwise
procedure was used to derive the best-fitting model. In
addition, we compared the survival and clinicopathologic
parameters of our treated group to 60 patients who under-
went PD alone and had no neoadjuvant therapy
(untreated group) during the same time period. Statistical
analysis was performed using Statistical Package for Social
Sciences software (forWindows 12.0, SPSS Inc., Chicago,
Ill). A 2-sided significance level of .05 was used for all sta-
tistical analyses.
RESULTS
Pathologic Features of the Treated Group
Post-therapy tumor size ranged from 0.1 cm to 8.5 cm,
with an average of 2.6 cm. According to theWorld Health
Organization classification standards, 152 cases (63%)
were well to moderately differentiated PDAC, and 88
cases (37%) were poorly differentiated PDAC. Dissection
of regional lymph nodes from resection specimens
yielded, on average, 22 lymph nodes (range, 5-50).
Lymph node involvement by metastatic disease was iden-
tified in 140 patients, with the number of positive lymph
nodes ranging from 1 to 21 nodes. On the basis of the
AJCC Staging Manual (seventh edition), 15 patients
(6%) had post-therapy pathologic stage I disease, 85
patients (36%) had stage IIA disease, and 140 patients
(58%) had stage IIB disease. Three patients with stage IV
disease because of positive intraoperative peritoneal wash-
ing on cytology were excluded from the study, as the num-
ber of cases was too small to be representative. No patient
had stage III disease. R0 resection was achieved in 213
patients (89%), 26 patients (11%) hadmicroscopic tumor
involvement of 1 or more surgical resection margins (R1),
and there were no R2 resections. In patients with R1
resection, 3 cases (1%) had tumor at the common bile
duct margin, 8 cases (4%) had tumor (5 cases) or carci-
noma in situ/high-grade dysplasia (3 cases) at the pancre-
atic margin, and 15 cases (6%) had tumor at the
retroperitoneal margin.
Survival Analysis
The median follow-up time in the treated group was 29.8
months (range, 7.6-122.3 months). At the time of last fol-
low-up, 154 patients died of PDAC, 11 patients died of
other causes, 15 patients were alive with PDAC, and 60
patients were alive with no clinical or radiographic evi-
dence of PDAC. Among all 240 patients, the DFS rates
were 52% at 1 year and 32% at 3 years, with a median
DFS of 15.1 months. The OS rates were 95% at 1 year
and 47% at 3 years with a median OS of 33.5 months.
The correlations of post-therapy pathologic tumor
stage (ypT) and AJCC stage with DFS and OS are shown
in Figure 1. Patients with ypT1 or ypT2 had better DFS
and OS than those with ypT3 (P ¼ .02 and P ¼ .003,
respectively, Fig. 1A, B). Patients with post-therapy stage
I disease had a significantly better DFS rate (87% at 1 year
and 67% at 3 years) compared with patients with stage
IIA (60% at 1 year and 39% at 3 years) and stage IIB dis-
ease (43% at 1 year and 23% at 3 years, P ¼ .0004). The
median DFS was 81.4 months among patients with stage
I disease, 22.0 months among patients with stage IIA dis-
ease, and 10.0 months among patients with stage IIB dis-
ease (Fig. 1C). OS was also significantly better in patients
with post-therapy stage I disease (100% at 1 year and 3
years) than patients with stage IIA disease (98% at 1 year
and 50% at 3 years) or patients with stage IIB disease
(94% at 1 year and 39% at 3 years) (P< .0001). The me-
dian OS was 104.4 months for patients with stage I dis-
ease, 39.5 months for patients with stage IIA disease, and
28.3 months for patients with stage IIB disease (Fig. 1D).
Both DFS and OS were better in patients with post-ther-
apy stage IIA PDAC than those with stage IIB PDAC
(P¼ .01 and P¼ .04, respectively, Fig. 1C, D).
Patients with negative regional lymph nodes (ypN0)
had a significantly better DFS and OS than those with
lymph node metastasis (ypN1)(P¼ .0003 and P< .0001,
respectively, Fig. 2A, B). Because the number of positive
lymph nodes has been shown to correlate with prognosis
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in patients with other gastrointestinal tract malignan-
cies,27-35 we further stratified our patients with regional
nodal metastasis into 2 groups: patients with 1 to 3 posi-
tive lymph nodes (ypN1a) and those with 4 or more posi-
tive lymph nodes (ypN1b). DFS and OS in relation to the
number of positive lymph nodes are illustrated in Figure
2C and D. The median DFS times were 27.1 months,
11.5 months, and 9.2 months among patients with ypN0,
ypN1a, and ypN1b disease, respectively (P ¼ .0001, Fig.
2C). The median OS times were 53.0 months, 32.8
months, and 24.1 months in patients with ypN0, ypN1a,
and ypN1b disease, respectively (P < .0001, Fig. 2D).
Our data demonstrated that the number of positive re-
gional lymph nodes correlated significantly with both
DFS and OS in patients with PDAC who received neoad-
juvant therapy and underwent PD.
Results from univariate Cox regression analysis for
DFS and OS are shown in Table 2. DFS was associated
with age (P ¼ .002), post-therapy primary tumor stage
(ypT) (P ¼ .03), regional lymph node status (ypN) (P <
.001), number of positive lymph nodes (P < .001), and
pathologic AJCC stage (P ¼ .001). OS was associated
with intraoperative blood loss (P ¼ .02), margin status
(P ¼ .02), ypT (P ¼ .005), ypN (P < .001), number of
positive lymph nodes (P < .001), and pathologic AJCC
stage (P < .001). There was no significant correlation
with either DFS or OS and sex, type of neoadjuvant ther-
apy administered, or tumor size.
Figure 1. Kaplan-Meier estimates of disease-free survival (A and C) and overall survival (B and D) among patients with pancreatic
ductal adenocarcinoma treated with neoadjuvant chemoradiation followed by pancreaticoduodenectomy are shown. Post-ther-
apy pathologic primary tumor stage (ypT) (A and B) and American Joint Committee on Cancer stage (C and D) predict both dis-
ease-free and overall survival.
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Two multivariate survival analyses were performed
to determine the prognostic significance of clinicopatho-
logic factors for DFS and OS, and the results are shown in
Table 3. In the first model, post-therapy pathologic AJCC
stage was an independent predictor for both DFS and OS
(P ¼ .002 and P < .001, respectively). In the second
model, the number of positive lymph nodes was a prog-
nostic factor for both DFS and OS independent of patient
age, intraoperative blood loss, tumor differentiation, ypT,
and margin status. Post-therapy primary tumor stage
(ypT) was an independent prognostic factor for OS (P ¼
.041), but not an independent prognostic factor for DFS
(P¼ .08). In bothmodels, patient age was an independent
prognostic factor for DFS, and tumor differentiation and
R0 resection status were independent prognostic factors
for OS. Intraoperative blood loss was significant for OS in
univariate analysis, but not in the multivariate models.
To evaluate whether neoadjuvant therapy improved
the clinical outcome in patients with PDAC, we com-
pared survival and clinicopathologic features of the treated
group to 60 consecutive patients who did not receive any
form of neoadjuvant therapy before PD (untreated group)
during the same time period at our institution. The me-
dian OS in the treated group was 33.5 months (2.5
months) and was better than the median OS of 26.5
months (3.4 months) in the untreated group (P ¼ .04,
Figure 2. Kaplan-Meier estimates of disease-free survival (A and C) and overall survival (B and D) among patients with pancreatic
ductal adenocarcinoma treated with neoadjuvant chemoradiation followed by pancreaticoduodenectomy are shown. Regional
lymph node status (ypN) (A and B) predicts both disease-free and overall survival. Patients with negative lymph nodes (ypN0)
have better disease-free and overall survival compared with patients with metastasis in 1 to 3 lymph nodes (ypN1a) and those
with metastasis in 4 or more lymph nodes (ypN1b) (C and D).
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Fig. 3A). The median DFS was also better in the treated
group than the untreated group; however, the difference
in DFS between these 2 groups was not statistically signif-
icant (P ¼ .08, Fig. 3B). In the treated group, metastatic
PDAC was identified in 58% (140 of 240) of the patients,
which was significantly lower than the untreated group
(75% [45 of 60], P ¼ .01). There were no significant dif-
ferences in tumor size, differentiation, margin status, and
other clinical parameters between these 2 groups (data not
shown).
DISCUSSION
In this study, we found that post-therapy pathologic
AJCC stage and the number of positive regional lymph
nodes are independent prognostic factors for both DFS
and OS in a consecutive cohort of 240 patients with
PDAC who received neoadjuvant chemoradiation fol-
lowed by PD treated at a single institution. In addition,
our study also found that tumor differentiation, ypT, and
margin status are independent prognostic factors for OS.
Our study highlights the importance of pathologic
Table 2. Univariate Cox Regression Analysis of Disease-Free and Overall Survival in Relation to Clinicopathologic Features
Characteristics No. of Patients Disease-Free Survival Overall Survival
HR (95% CI) P HR (95% CI) P
Age, y 240 0.97 (0.96-0.99) .002a 0.99 (0.97-1.00) .13
Sex
Female [ref] 97 1.00 1.00
Male 143 1.00 (0.74-1.36) 1.0 1.13 (0.82-1.56) .46
Blood loss, mL 238 1.00 (1.00-1.00) .07 1.00 (1.00-1.00) .02a
Neoadjuvant therapyb
Group 1 [ref] 42 1.00 1.00
Group 2 77 0.77 (0.48-1.22) .26 0.69 (0.43-1.11) .13
Group 3 77 1.27 (0.81-1.98) .30 0.94 (0.59-1.50) .79
Group 4 37 1.45 (0.86-2.44) .16 0.95 (0.54-1.65) .85
Group 5 7 1.24 (0.48-3.22) .65 1.00 (0.39-2.61) .99
Tumor size
£ 2 cm [ref] 91 1.00 1.00
>2 cm 149 1.30 (0.95-1.78) .11 1.25 (0.89-1.74) .19
Tumor differentiation
Well-moderate [ref] 152 1.00 1.00
Poor 88 1.28 (0.94-1.75) .12 1.36 (0.99-1.88) .06
Margins
Negative [ref] 213 1.00 1.00
Positive 27 1.33 (0.85-2.08) .22 1.72 (1.09-2.71) .02a
Pathologic tumor stage
ypT1-ypT2 [ref] 19 1.00 1.00
ypT3 221 2.07 (1.09-3.94) .03a 3.26 (1.44-7.39) .005a
Lymph node status
Negative [ref] 100 1.00 1.00
Positive 140 1.78 (1.30-2.45) <.001a 2.00 (1.43-2.81) <.001a
Number of positive lymph nodes <.001a <.001a
0 [ref] 100 1.00 1.00
1-3 97 1.57 (1.12-2.22) .01a 1.76 (1.22-2.55) .002a
‡4 43 2.42 (1.60-3.65) <.001a 2.67 (1.74-4.11) <.001a
AJCC stage .001a <.001a
IA-IB [ref] 15 1.00 1.00
IIA 85 2.08 (0.94-4.57) .07 4.40 (1.37-14.15) .013a
IIB 140 3.31 (1.53-7.14) .002a 7.34 (2.32-23.21) .001a
Abbreviations: AJCC, American Joint Committee on Cancer; CI, confidence interval; HR, hazard ratio; ref, reference.
a Statistically significant.
b According to groups outlined in Table 1.
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Table 3. Multivariate Cox Regression Analysis of Disease-Free and Overall Survival in Relation to Clinicopathologic Features
Characteristics No. of Patients Disease-free Survival Overall Survival
HR (95% CI) P HR (95% CI) P
First model
Age, y 240 0.98 (0.96-0.99) .004a 0.99 (0.97-1.01) .29
Blood loss, mL 238 1.00 (1.00-1.00) .24 1.00 (1.00-1.00) .12
Tumor differentiation
Well-moderate [ref] 152 1.00 1.00
Poor 88 1.19 (0.87-1.63) .27 1.43 (1.03-1.99) .034a
Margins N/A
Negative [ref] 213 — 1.00
Positive 27 — 1.64 (1.02-2.62) .040a
AJCC stage .002a <.001a
IA-IB [ref] 15 1.00 1.00
IIA 85 2.41 (1.09-5.34) .03a 4.36 (1.35-14.05) .014a
IIB 140 3.43 (1.59-7.39) .002a 6.95 (2.19-22.00) .001a
Second model
Age, y 240 0.98 (0.96-0.99) .007a 0.99 (0.98-1.01) .47
Blood loss, mL 238 1.00 (1.00-1.00) .26 1.00 (1.00-1.00) .12
Tumor differentiation
Well-moderate [ref] 152 1.00 1.00
Poor 88 1.23 (0.90-1.69) .19 1.50 (1.08-2.09) .017a
Margins N/A
Negative [ref] 213 — 1.00
Positive 27 — 1.63 (1.02-2.61) .041a
Pathologic tumor stage
ypT1-ypT2 [ref] 19 1.00 1.00
ypT3 221 1.81 (0.92-3.55) .084 2.40 (1.03-5.58) .041a
Number of positive lymph nodes .010a .001a
0 [ref] 100 1.00 1.00
1-3 97 1.34 (0.93-1.92) .114 1.47 (1.01-2.14) .046a
‡4 43 1.96 (1.27-3.02) .002a 2.32 (1.50-3.60) <.001a
Abbreviations: AJCC, American Joint Committee on Cancer; CI, confidence interval; HR, hazard ratio; N/A, not available; ref, reference.
a Statistically significant.
Figure 3. Kaplan-Meier estimates of overall (A) and disease-free survival (B) are shown of patients with pancreatic ductal adeno-
carcinoma treated with neoadjuvant chemoradiation followed by pancreaticoduodenectomy (PD) (treated group, n ¼ 240) and
those who had no neoadjuvant therapy before PD (untreated group, n ¼ 60).
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evaluation and post-therapy tumor staging in predicting
prognosis of patients with PDAC who received neoadju-
vant therapy and subsequently underwent PD.
In the treatment of patients with PDAC, neoadju-
vant therapy has several potential advantages, including
identifying patients who are likely to benefit the most
from surgery, providing early treatment of micrometa-
static disease, and potentially down-staging the tumor in
borderline resectable cases, thereby increasing the rate of
complete resection and reducing local recurrence. Several
studies, including 2 large trials from our institution, have
reported median survival durations of up to 34 months in
patients with resectable PDAC treated with neoadjuvant
chemoradiation followed by PD.4,7,8 Evans et al studied
64 patients who were treated with neoadjuvant gemcita-
bine-based chemoradiation and subsequent PD, and
reported a median OS of 34 months.4 A phase 2 trial
reported by Varadhachary et al showed a median OS of
31 months in the 52 patients who received preoperative
gemcitabine and cisplatin chemotherapy followed by
gemcitabine-based chemoradiation and then underwent
PD.8 In the current study of 240 patients, which includes
146 patients (61%) who were treated under the protocols
reported by Evans et al and Varadhachary et al,4,8 the me-
dian OS was 33.5 months, with 1-year and 3-year OS
rates of 95% and 47%, respectively. No survival difference
was seen among patients who received different neoadju-
vant regimens.
Our study showed that pT stage, tumor differentia-
tion, andmargin status correlated with OS by multivariate
analysis, similar to the previous studies of patients with
PDAC who underwent surgery with or without adjuvant
chemoradiation.13-18,22,23 However, we did not find sig-
nificant correlation of these parameters with DFS. In our
study, the R0 resection rate was 89%, which is consistent
with the reported R0 resection rates of 72% to 95% in
patients with PDAC treated with a variety of neoadjuvant
chemoradiation protocols followed by surgery.5,7,9,36
Patients with R0 resection had a significantly better OS
than patients with R1 resection (35.5 vs 24.0 months, P
¼ .02). Because the vast majority of our cases (92%, 221
of 240) had ypT3 tumor, with only 19 (8%) cases catego-
rized as either ypT1 (16 cases) or ypT2 (3 cases), the cor-
relation of ypT with survival may not be fully
representative for patients with ypT1 or ypT2 tumors.
However, our data demonstrated that patients with ypT3
had worse DFS and OS than those with ypT1 and ypT2
tumors by univariate analysis, and had a worse OS by
multivariate analysis.
Pathologic AJCC stage and lymph node status are
important independent prognostic factors for patient out-
come in various types of human malignancies.13,15,17-21
Our study demonstrated that post-therapy pathologic
AJCC stage is an independent prognostic factor for both
DFS and OS in patients with PDAC treated with neoad-
juvant therapy followed by PD. Our results are consistent
with findings from previous studies demonstrating that
post-therapy pathologic AJCC stage predicts outcome for
patients who undergo preoperative chemoradiation fol-
lowed by surgery for carcinoma of the esophagus,37 stom-
ach,38,39 and rectum.40 In addition, we showed that
lymph node status correlated with both DFS and OS in
patients with PDAC who received neoadjuvant
chemoradiation.
Recent studies suggest that the lymph node ratio
(number of positive lymph nodes to the total number of
lymph nodes harvested) may be a better predictor of sur-
vival than lymph node status alone in patients with
PDAC.2,41,42 Berger et al evaluated 128 patients who
underwent PD, including 48 patients who received neo-
adjuvant chemoradiation and 80 patients who received
postoperative adjuvant chemotherapy.41 By using a cutoff
value of 15%, they found that lymph node ratio was a sig-
nificant prognostic indicator of both DFS and OS by uni-
variate analysis, but failed to detect significance by
multivariate analysis. Similar results were reported by
Sierzega et al in 96 patients who underwent PD with or
without adjuvant chemoradiation using a lymph node ra-
tio of 20% as a cutoff.42 However, the total number of
lymph nodes was not found to have prognostic signifi-
cance for patient survival in both studies.41,42 Consistent
with their findings are results from 2 randomized con-
trolled trials that have examined the role of extended
lymphadenectomy in PDAC, and have found no signifi-
cant advantage in survival among patients with increased
lymph node harvest.43,44 In this study, we grouped our
patients into ypN0 (no lymph node metastasis), ypN1a
(metastasis in 1-3 lymph nodes), and ypN1b (metastasis
in 4 or more lymph nodes) based on the AJCC staging cri-
teria for lymph nodes in other gastrointestinal malignan-
cies.26 We found that the number of positive lymph
nodes is an independent prognostic factor for both DFS
and OS by univariate and multivariate analyses. The me-
dian DFS and OS for patients with ypN1a disease were
11.5 months and 32.8 months, respectively, and were sig-
nificantly better than the DFS of 9.2 months and OS of
24.1 months for those with ypN1b disease (P¼ .03 and P
¼ .04, respectively). Our results showed that the number
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of positive lymph nodes is an important prognostic factor
in patients with PDAC who received neoadjuvant
therapy.
In this study, we also found that patients with
PDAC who received neoadjuvant therapy and subse-
quently underwent PD had better OS and lower fre-
quency of lymph node metastasis than those who had no
neoadjuvant therapy. Retrospectively comparing survival
in a cohort that has undergone neoadjuvant therapy fol-
lowed by selection of patients developing progressive dis-
ease before surgery with another cohort that has not
undergone such a selection has significant limitations. In
addition, we do not have the denominator of total num-
ber of patients who received neoadjuvant therapy, but did
not undergo PD because of progressive disease. However,
among the 240 patients in our treated group, 146 patients
(61%) were treated on protocols reported by Evans et al
and Varadhachary et al.4,8 In these 2 trials, PD was per-
formed successfully in 74% and 66% patients who com-
pleted neoadjuvant therapy, and the median OS of all
unselected patients was 22.7 months and 17.4 months,
respectively.4,8 A comparison group in the literature con-
sisting of all patients who underwent surgery first with
anticipation of receiving postoperative adjuvant therapy
(including those who did and did not receive intended
therapy) is not available. Randomized clinical trials are
needed to further examine the role of neoadjuvant therapy
in patients with PDAC.
In summary, our study demonstrated that post-ther-
apy pathologic AJCC stage, the number of positive lymph
nodes, tumor differentiation, margin status, and ypT were
independent prognostic factors for survival in patients
with PDAC who received neoadjuvant chemoradiation
and subsequently underwent PD. Pathologic evaluation
of PD specimen and post-therapy pathologic tumor stag-
ing remain the key factors in predicting clinical outcome
in this group of patients.
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